Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment

Open-label, Prospective, Multicenter Study to Evaluate the Cutera Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment for the Treatment of Moderate to Severe Acne Scars

The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of moderate to severe acne scars.

Study Overview

• Status: Completed
• Conditions: Acne; Scarring
• Intervention / Treatment: Device: Enlighten™ Laser and a MLA Attachment

Detailed Description

This is an open-label, prospective, multicenter, pivotal study in approximately 15 male or female subjects, age 18 to 65 years who desire laser treatment for the improvement of moderate to severe acne scars. Subjects will receive laser treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment. Subjects will return to the site after all study treatments have been delivered for a follow-up visit at 12 weeks following their final study treatment.

• Study Type: Interventional
• Enrollment (Actual): 4
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Brisbane, California, United States, 94005
      • Cutera Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Subject must be able to read, understand and sign the Informed Consent Form.
2. Female or Male, 18 to 65 years of age (inclusive).
3. Fitzpatrick Skin Type I - VI.
4. Subject desires treatment for acne scars and wishes to undergo laser treatments for improvement.
5. Subject has bilateral moderate to severe signs of facial acne scarring.
6. Must be willing to have Cutera enlighten laser with the Micro-Lens Array handpiece attachment treatments and able to adhere to the treatments, follow-up visit schedule, and post-treatment care instructions.
7. Willing to have very limited sun exposure and use sunscreen on the treatment area every day for the duration of the study, including the follow-up period.
8. Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation (educational and/or marketing), publications, and any additional marketing purposes.
9. Agree to not undergo any other procedure(s) or treatment(s) for acne scars during the study and has no intention of having such procedures performed during the course of the study.
10. For female subjects: not pregnant or lactating and is either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.,

Exclusion Criteria:

1. Participation in a clinical trial of another drug, or device administered to the treatment area, within 6 months prior to enrollment or during the study.
2. Any type of prior cosmetic treatment to the target area within 6 months of study participation, such as laser procedures, facial fillers, i.e. (Bellafill) and those used for general aesthetic correction, facial peel, lightening creams, or facial surgery.
3. Use of prescription topicals in the treatment area within one month prior to treatment or use of topical agents one week prior to treatment that may cause facial sensitivity.
4. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including but not limited to, open lacerations or abrasions, hidradenitis, rash, infection , or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion).
5. Pregnant and/or breastfeeding, or planning to become pregnant.
6. Significant concurrent illness, such as diabetes mellitus, immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or using immunosuppressive medication.
7. Hypersensitivity to light exposure.
8. Any use of medication that is known to increase sensitivity to light according to the Investigator's discretion.
9. History of keloid scarring, hypertrophic scarring or abnormal wound healing or prone to bruising.
10. Has a history of squamous cell carcinoma or melanoma in the treatment area.
11. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
12. A history or active skin condition that in the opinion of the Investigator may interfere/confound with the treatment.
13. History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
14. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
15. History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation, or any that are considered not acceptable by the study investigator.
16. Has used oral isotretinoin (Accutane or therapeutic vitamin A supplements of ≥ 10,000 units per day) within 12 months of initial treatment or plans on using during the course of the study (note: skin must regain its normal degree of moisture prior to treatment, e.g. lack of noticeable skin flaking and peeling).
17. Excessively tanned or active sun tan in facial area to be treated, or unable/unlikely to refrain from tanning during the study.
18. Excessive facial hair in the area to be treated (beards, sideburns, and/or moustache,) that would interfere with diagnosis, assessment, and treatment.
19. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study, including excessive alcohol or drug abuses, or a condition that would compromise the subject's ability to comply with the study requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Enlighten™ Laser and a MLA Attachment; Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment	Device: Enlighten™ Laser and a MLA Attachment; Subjects will receive treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acne Scarring Improvement	An improvement in Acne Scarring of at least one point on the Acne Scar Assessment Scale (ASAS):(1=clear scarring, 2=Very Mild scarring, 3=Mild scarring, 4=Moderate scarring or 5=Severe scarring) at the 12 weeks post final treatment	Baseline, and at 12 weeks post final treatment (up to 30 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acne Scarring Assessment	Measuring the efficacy of Cutera enLighten device with MLA handpiece attachment for Acne scarring Improvement as assessed by Investigator using the Acne Scar Assessment Scale (ASAS):(1=clear, 2=Very Mild, 3=Mild, 4=Moderate or 5=Severe) after 2nd treatment, and every treatment thereafter, at 6 weeks post final treatment and 12 weeks post final treatment	Baseline, post-treatment #2 through study completion, an average of 1 year, 6 weeks post final treatment and 12 weeks post final treatment
Physician's Global Assessment	Measuring the efficacy of Cutera enLighten device with MLA handpiece attachment for improvement of the overall skin quality as assessed by Investigator using the Physician's Global Aesthetic Improvement Scale: +3=Significant Improvement (66 - 100%), +2=Moderate Improvement(36 - 65%), +1=Mild Improvement(1 - 35%) and 0=No Change(0%) after 2nd treatment, and every treatment thereafter, 6 weeks post final treatment and 12 weeks post final treatment	post-treatment #2 through study completion, an average of 1 year, 6 weeks post final treatment and 12 weeks post final treatment
Skin Quality Assessment	Measuring the efficacy of Cutera enLighten device with MLA handpiece attachment for Skin quality as assessed by Investigator using Skin Quality Rating for Radiance(1=No radiance to 10=Maximum radiance), Smoothness(1=Very Rough to 10=Very Smooth), Pigmentation(1=Very irregular pigmentation to 10=Very uniform pigmentation), Erythema(1=Intense redness to 10=No redness) and Pore size(1=Very large pores to 10=Minimal pores) after 2nd treatment, and every treatment thereafter, 6 weeks post final treatment and 12 weeks post final treatment	Baseline, and post-treatment #2 through study completion, an average of 1 year, 6 weeks post final treatment and 12 weeks post final treatment
Subject Assessment of Acne scar Treatment	Satisfaction level and assessment of Acne Scar improvement as assessed by Subject: Where 2 = Extremely Satisfied, 1=Satisfied, 0=Neutral, -1=Unsatisfied; and -2=Extremely Unsatisfied at 12 weeks post final treatment.	12 week post final treatment
Histological Evaluation of tissue, if taken	Histological evaluation of tissue from biopsies of treated vs. untreated	Biopsy times are: Baseline (untreated), and immediately (or up to 72 hours) after any one treatment, or 3 months post initial treatment

Collaborators and Investigators

• Sponsor: Cutera Inc.
• Investigators: Principal Investigator: Stephen Ronan, M.D., Cutera Research Center

Study record dates

Study Major Dates

• Study Start (Actual): August 15, 2017
• Primary Completion (Actual): May 30, 2018
• Study Completion (Actual): May 30, 2018

Study Registration Dates

• First Submitted: February 1, 2018
• First Submitted That Met QC Criteria: February 6, 2018
• First Posted (Actual): February 13, 2018

Study Record Updates

• Last Update Posted (Actual): September 26, 2023
• Last Update Submitted That Met QC Criteria: September 1, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Fibrosis; Cicatrix
• Other Study ID Numbers: C-17-ML03

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes